Shane Gleason

Fidelity Management & Research Co. (FMR) is a SEC-registered investment advisor headquartered in Boston, Massachusetts. The firm was founded in 1946 and is a subsidiary of FMR LLC, also known as Fidelity Investments. FMR provides investment supervisory services, which include sub-advisory services, to Fidelity's family of mutual funds and exchange-traded funds, qualified tuition programs, privately offered unregistered investment funds, separately managed account clients, and various other institutional accounts.

Curon Medical, Inc. develops, manufactures and markets proprietary products for the treatment of gastrointestinal disorders. Its products consist of radiofrequency generators and single-use disposable devices. The company was founded on May 1, 1997 and is headquartered in Fremont, CA.

Lipid Sciences, Inc. is a biotechnology company that is engaged in research and development of products and processes intended to treat major medical indications such as cardiovascular disease and viral infections in which lipids or fat components, play a key role. The company is focused on applications of technologies in two main areas: cardiovascular disease, using the HDL Therapy platform and viral infections, using the Viral Immunotherapy platform. HDL Therapy focuses on developing treatments for the reversal of atherosclerosis, which is the leading cause of heart attacks, strokes and peripheral vascular disease. It was formerly known as NZ Corp. The company was founded in 1908 and is headquartered in Pleasanton, CA.

Velocimed LLC develops, manufactures, and markets medical devices. The firm's products are used in cardiology and neurology applications. The company was founded in 2001 by Jay Schmelter, Michael Berman, and Dennis W. Wahr and is headquartered in Maple Grove, MN.

InspireMD Ltd. is a medical device company, which engages in the development and commercialization of platform technology for the treatment of vascular and coronary disease. It offers MicroNet stent, a device designed to trap and seal thrombus and plaque against the vessel wall, preventing embolization. The company was founded in 2005 and is headquartered in Tel Aviv, Israel.

CardioFocus, Inc. engages in the development and market of catheter-based approach to treating atrial fibrillation. The company was founded by Edward Sinofsky in 1990 and is headquartered in Marlborough, MA.

RiverVest Venture Management LLC (RiverVest Venture Partners) is a venture capital firm founded in 2000 by Thomas Melzer, Craig Andrew and Jay Schmelter. The firm is headquartered in St. Louis, Missouri.

Cameron Health, Inc. develops medical devices for patients and medical professionals. It has developed a totally subcutaneous implantable defibrillator (S-ICD) system that remedies many of the issues associated with traditional implantable cardioverter defibrillators. The company was founded on August 21, 2000 and is headquartered in San Clemente, CA.

Cornell University is an educational institution that offers undergraduate and post graduate programs. It was founded in 1865 and is based in Ithaca, NY.

Founded in 1898, Northeastern University is a private research university located in the heart of Boston. Northeastern teaches worldwide experiential learning, urban engagement, and interdisciplinary research that meets global and societal needs. The University offers a range of undergraduate and graduate programs leading to degrees through the doctorate in nine colleges and schools.

The University of St. Thomas is an institution that values diversity, equity, and inclusion. The private company is based in St. Paul, MN. It offers over 150 undergraduate majors and minors, as well as graduate programs in various fields such as business, engineering, law, education, social work, and arts and humanities. The University of St. Thomas was founded in 1885 by John Ireland.

Braille Institute of America, Inc. offers different services to people with vision loss. The company was founded by Robert J. Atkinson in 1919 and is headquartered in Los Angles, CA.

Osiris Investment Partners LLC is an independent hedge fund manager headquartered in Boston, Massachusetts. The firm was founded by Paul S. Stuka and provides investment advice to high-net-worth clients.

UltraShape redefines aesthetic medicine by developing, manufacturing and marketing innovative non-invasive technologies for fat cell destruction and body sculpting. The company develops and markets clinically proven safe and effective solutions that enhance the lives of patients. The UltraShape proprietary technology employs pulsed (non-thermal) focused ultrasound that instantly, selectively and permanently destroys fat cells without affecting surrounding structures. Founded in 2000, UltraShape has sold Contour I devices in more than 50 countries, demonstrating safety and efficacy. The UltraShape Contour I system, is authorized for marketing outside the U.S. It is the first clinically proven non-invasive solution that offers measurable lasting body sculpting results for men and women with no need for maintenance treatments. The UltraShape system has been shown to be safe and effective in a multi-center controlled trial and numerous other peer-reviewed published independent clinical studies. The device is designed to produce mechanical, non-thermal, acoustic effects which target and selectively destroy (breakdown) fat cells, leaving surrounding critical structures such as skin, blood vessels, nerves, and connective tissue intact. The latest Contour I V3 system uses Vertical Dynamic Focus™ (VDF) pulsed (non-thermal) focused ultrasound that instantly and permanently destroys fat cells providing patients a convenient noninvasive no-downtime solution to reduce localized fat deposits and body circumference. The UltraShape procedure is based on a natural fat clearance process where triglycerides and cell debris from the destroyed fat cells are processed by the body's natural physiological and metabolic pathways. These pathways are the same that handle fat during weight loss. Results from UltraShape's peer-reviewed published multi-center controlled clinical trial and other independent clinical studies show that the released triglycerides do not accumulate to a clinically significant extent in the blood or liver. Over 200,000 patient treatments have been performed worldwide with the Contour I showing high patient satisfaction while demonstrating safety and efficacy. The UltraShape procedure is guided by proprietary real-time tracking and guidance technology designed to deliver smooth, uniform body contouring results. The software guides the operator through a pres-determined treatment algorithm designed to minimize risk of contour irregularities, a common side effect of invasive and non-invasive procedures. The UltraShape procedure is performed during a convenient, 'walk-in, walk-out' session carried out in an office-based environment; it requires no anesthesia or sedation. After treatment, patients immediately resume their daily routines with no need for maintenance treatments. The UltraShape Contour I received the CE Mark in 2005 and a medical device license from Health Canada in 2007. The Contour I system is not available for sale in the U.S; the Contour Plus system is an investigational product limited by U.S. law to investigational use only.

Equinox Ophthalmic, Inc. operates as a biotechnology company. It specializes in cataract, corneal and glaucoma surgery. The company was founded by John Berdahl and is headquartered in Sioux Falls, SD.

ClearCut Medical Ltd. develops proprietary technology and tools for removal of cancer. Its product ClearSightTM MRI System, focuses on breast cancer lumpectomy for intraoperative margin assessment of surgically removed lumps. The firms applications include breast cancer biopsies, margin assessment of skin cancer, prostate cancer, colorectal cancer and lung cancer tissue microstructure. The company was founded by Eyal Kolka and Erez Golan in 2010 and is headquartered in Rehovot, Israel.

Pharmacentra LLC provides marketing and communications programs for the pharmaceutical and insurance industries. The private company is based in Norcross, GA. The CEO of the company is Dan Berman.

EndoSpan Ltd. develops novel endovascular system for endovascular aortic aneurysm repair. The firm is opening up options for repairing aneurysms and dissections in patients with anatomy previously unsuitable for endovascular therapy. The company was founded by Rafi Benary and Alon Shalev in 2009 and is headquartered in Herzlia, Israel.

SoniVie Ltd. engages in the development of a system for the treatment of pulmonary hypertension. Its products include Therapeutic Intra-Vascular Ultrasound (TIVUS) system, an intravascular, catheter-based technology that can cause denervation of nerves surrounding blood vessels and other structures like the bronchus. The company was founded by Moshe Arkin in 2014 and is headquartered in Rosh Haayin, Israel.

PulmOne Advanced Medical Devices Ltd. develops devices designed to allow lung function testing. It manufactures and distributes the MiniBox, an office based solution providing complete lung function testing in a portable device. The company was founded by Avi Lazar in 2006 and is headquartered in Raanana, Israel.

Part of Medtronic Plc, Mazor Robotics LLC is a company that specializes in the Mazor X Stealth Edition robotic guidance platform. The company is based in Orlando, FL. The platform is equipped with advanced software, robotic technologies, navigation, and instrumentation to support predictable surgical procedures. Christopher Prentice has been the CEO of the company since 2014.

RxSight I LLC, a special purpose fund, formed to invest in RxSight, Inc.

Flying L Management LLC (Flying L Management) is a venture capital firm founded in 2016. The firm is headquartered in Newport beach, California.

Owlytics Healthcare operates personalized physiology-tracking health detection platform. The company was founded by Gill Zaphrir and Yaron Recher in 2015 and is headquartered in Tel Aviv, Israel.

Vialase, Inc. provides healthcare services. The company is headquartered in Aliso Viejo, CA.

Caliber Imaging & Diagnostics, Inc. operates as a medical technologies company. It designs, develops, and markets imaging solutions for use in applications such as dermatology, neurological sciences, developmental biology, pathology, and translational research. The firm offers VIVANET and VIVASCAN. The company was founded in 1991 and is headquartered in Andover, MA.

Qart Medical Ltd. is a medical, a clinical-stage medtech company, addressing the global infertility epidemic. The company was founded by Alon Shalev and Natan T. Shaked and is headquartered in Israel.

CardiacSense Ltd. is a digital health company based in Caesarea, Israel. The Israeli company has developed a medical watch that integrates proprietary patent-protected sensors and software algorithms to provide continuous measurement of parameters such as core temperature, respiratory rate, blood pressure, oxygen saturation, and heart rate at CE and FDA-mandated accuracies. This provides an alternative to costly and complex invasive devices, addressing the increasing demand for remote patient monitoring and tele-health. The private company was founded in 2009 by Eldad Shemesh and Liat Shemesh, with Eldad Shemesh serving as the CEO since incorporation.

Neurolens, Inc. is a company that commercializes breakthrough technology to improve vision care. The company's patented contoured prism technology provides visual comfort for the nearly 65% of US adults who complain of headaches, neck/shoulder pain, and eyestrain when using digital devices, reading, or doing detail work. The company is based in Coppell, TX. Inspired by a breakthrough discovery linking optometry and neurology, Neurolens is unlocking a new dimension of vision care. The Neurolens contoured prism design helps the eyes work together comfortably, bringing the eyes into alignment to relieve painful symptoms. The technology is only available to independent eye care providers. The company was founded in 2012 by Davis Corley, and Pierre Bertrand has been the CEO of the company since 2019.

Aurion Biotech, Inc. is a clinical-stage biotech company with offices in multiple locations. Aurion Biotech has initiated clinical trials in the US in 2023. The company is based in Seattle, WA. The company's mission is to restore vision to millions of patients with life-changing regenerative therapies. Aurion Biotech has received the prestigious Prix Galien award for best start-up in biotech. The company's first candidate is an off-the-shelf, clinically validated cell therapy for corneal care, which has received regulatory approval. The company is privately held and backed by leading investors, including Deerfield, Alcon, Petrichor, Flying L Partners, Falcon Vision/KKR, and Visionary Ventures. Greg Kunst has been the CEO of the company since 2021.